Insider Selling: Aura Biosciences, Inc. (NASDAQ:AURA) CTO Sells 2,151 Shares of Stock

Aura Biosciences, Inc. (NASDAQ:AURA) CTO Mark Plavsic sold 2,151 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $7.75, for a total value of $16,670.25. Following the transaction, the chief technology officer now directly owns 209,456 shares of the company’s stock, valued at $1,623,284. This represents a 1.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Aura Biosciences Price Performance

Shares of Aura Biosciences stock opened at $7.65 on Thursday. Aura Biosciences, Inc. has a 1 year low of $6.63 and a 1 year high of $12.38. The firm’s 50-day moving average is $8.02 and its 200 day moving average is $8.74. The stock has a market cap of $382.12 million, a price-to-earnings ratio of -4.42 and a beta of 0.29.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on AURA. HC Wainwright reissued a “buy” rating and set a $22.00 price target on shares of Aura Biosciences in a research report on Thursday, November 14th. Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $23.00.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. BNP Paribas Financial Markets bought a new stake in shares of Aura Biosciences during the fourth quarter valued at approximately $50,000. China Universal Asset Management Co. Ltd. bought a new position in Aura Biosciences in the 4th quarter valued at approximately $87,000. ProShare Advisors LLC purchased a new stake in Aura Biosciences during the 4th quarter valued at $127,000. Harvest Investment Services LLC bought a new stake in shares of Aura Biosciences in the 4th quarter worth $133,000. Finally, AlphaQuest LLC purchased a new position in shares of Aura Biosciences in the fourth quarter worth $136,000. 96.75% of the stock is owned by hedge funds and other institutional investors.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.